F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
NY TimesPaywall
Read Full Article at NY Times →Ad Slot — In-Article (728x90)
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
This is a summary. For the full story, read the original article at NY Times.
Original source: NY Times